Onco-Innovations Ltd. ( (TSE:ONCO) ) just unveiled an update.
Onco-Innovations Ltd.’s subsidiary, Inka Health, has completed a significant analytical project for AstraZeneca Canada, showcasing its expertise in pharmaceutical evidence generation. This work has led to the development of two studies that will be presented at ISPOR 2025, highlighting innovative methodologies to improve the credibility and applicability of real-world evidence in regulatory and market access decisions. These advancements are expected to influence drug evaluation processes and regulatory strategies, reinforcing Inka Health’s position in the industry.
More about Onco-Innovations Ltd.
Onco-Innovations Ltd. operates in the pharmaceutical analytics industry, focusing on developing rigorous methodologies to enhance the reliability of real-world data in healthcare decision-making. Its subsidiary, Inka Health Corp., plays a significant role in advancing evidence generation and precision medicine, particularly through its proprietary analytics platform, SynoGraph.
YTD Price Performance: 84.71%
Average Trading Volume: 439,428
Learn more about ONCO stock on TipRanks’ Stock Analysis page.